Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from JJ.

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

The Independent UK

Morning Brief: Top Financial Stories Dominating on Wednesday, April 27

Reuters Kellogg Sues British Government Over New Sugar Rules

Benzinga

Johnson & Johnson Initiates Legal Action Against Entities Selling Fake HIV Medications

Johnson & Johnson (NYSE: JNJ) has filed the latest lawsuit to combat illicit sales of drugs in the U.S., alleging that several drug distributors and pharmacies are selling counterfeit versions of its HIV drugs.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

JNJ, McKesson, Endo Settle $275M Opioid Claims With Alabama: Reuters

Alabama reached $276 million in settlements with Johnson & Johnson (NYSE:JNJ), McKesson Corporation (NYSE:MCK), and Endo International Plc (NASDAQ:ENDP), resolving claims on the opioid addiction crisis, the state attorney general said. McKesson will pay $141 million. JNJ and Endo will pay $70.3 million and $25 million, respectively, Alabama Attorney General Steve Marshall said in a statement. The three…

Benzinga

Stock Market Gains On Housing News, Lower Oil Prices; Positive Earnings Lift Stocks

The stock market gained broadly Tuesday as housing news and lower oil prices lifted stocks, and as more earnings came in.

Investors Business Daily

JNJ Stock Alert: Buy Johnson & Johnson on Push to All-Time Highs?

Johnson & Johnson stock is hitting all-time highs on earnings. Is the stock a buy?

The Street

Stock Market Up Nearly 1% As Earnings Pour In; These 2 Stocks Top Buy Points

The Dow Jones Industrial Average jumped 1% after two of its components reported earnings this morning.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

J&J suspends COVID-19 vaccine sales forecast

Johnson & Johnson is suspending sales forecasts for its COVID-19 vaccine only a few months after saying the shot could bring in as much as $3.5 billion this year

The Independent UK

Why J&J Is Shifting Its Focus From Covid Shots — And Seeing A Stock Resurgence

Johnson & Johnson slashed its 2022 guidance on Tuesday and cut its Covid vaccines outlook entirely — but JNJ stock popped at the open.

Investors Business Daily

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.